ArticleEuropean journal of medical research2025
A population-based analysis of a risk stratification system for predicting radiotherapy benefits in invasive breast carcinoma of no special type with medullary pattern.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInvasive breast carcinoma of no special type (IBC-NST) with medullary pattern is a rare histological subtype, accounting for 3-5% of breast malignancies. Its distinct clinicopathological features and uncertain benefit from radiotherapy (RT) pose unique therapeutic challenges. Current guidelines extrapolate treatment protocols from invasive ductal carcinoma, yet prognostic heterogeneity and the absence of validated biomarkers underscore the need for precision stratification tools to guide RT decisions.
methodsUsing data from the SEER database (2010-2018), we conducted univariate and multivariate Cox regression analyses to develop a prognostic stratification model and stratified the whole cohort into different risk groups to determine the optimal candidates to benefit from radiotherapy. The accuracy of the nomogram was evaluated by discrimination and calibration evaluation.
resultsAmong 667 eligible patients, 535 were allocated to the training set and 132 to the validation set (8:2 ratio). Five independent prognostic factors were identified: age, T stage, N stage, molecular subtype, and chemotherapy status. These were incorporated into a nomogram predicting 3- and 5-year overall survival (OS). Using an optimal cutoff, patients were stratified into low- and high-risk groups. Radiotherapy significantly improved OS in low-risk patients compared to those not receiving RT (P = 0.017), but not in high-risk patients (P = 0.47). The model demonstrated strong predictive performance, with 3- and 5-year AUC values of 0.777 and 0.775 in the training set, and 0.747 and 0.712 in the validation set. Calibration curves indicated close agreement between predicted and observed outcomes.
conclusionWe developed and validated a prognostic nomogram for IBC-NST with medullary pattern that accurately stratifies patients by risk. Our findings indicate that radiotherapy is associated with a survival benefit primarily in low-risk patients, offering a practical tool to optimize RT personalization and avoid overtreatment in high-risk individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.